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Introduction: Cardiac rhythm management devices (CRMDs) have proven their clinical effectiveness for pa-
tients with heart rhythm disorders. Little is known about safety and complication rates during the implanta-
tion of these devices. This study demonstrated the complication rates related to CRMD implantation, and es-
timated the additional hospital stay and cost associated with the management of complications.
Methods: During a period of one year, a total of 464 consecutive recipients underwent CRMD implantation 
and were followed for 2 years. Finally, data were analyzed for 398 patients who completed the two-year fol-
low up, resulting in a total of 796 patient-years.
Results: Of the 201 patients with initial pacemaker (PM) implantations, 6 (2.99%) had seven complications 
(5 patients had lead dislodgement, 1 of them twice), and 1 patient developed pocket infection. Of the 117 
PM replacements, 1 (0.85%) patient developed a complication (pocket erosion). Two patients with compli-
cations (1 with an initial PM and 1 with a replacement) died before completing the follow up for reasons un-
related to cardiac causes. There were no complications in either initial implantations (69 patients) or replace-
ments (11 patients) of implantable cardioverter-defibrillators. The average prolongation of the hospital stay 
was 7 days, ranging from 1 to 35 days, resulting in €17,411 of total additional direct hospital costs.
Conclusion: This study found relatively low rates of complications in patients undergoing CRMD implanta-
tion, initial or replacement, in our center, compared with other studies. The additional hospitalization days 
and costs attributable to these complications depend on the nature of the complication.
T he development of implantable technology for cardiac rhythm management remains one of the 
seminal achievements of the second half 
of the 20th century.1 Pacemakers (PMs) 
decrease mortality and improve quality of 
life,2 while implantable cardioverter-defi-
brillators (ICDs) have been shown to re-
duce mortality in patients at risk of sud-
den cardiac death, in both primary3-5 and 
secondary prevention.6,7 Nowadays, PMs 
and ICDs are implanted on a large and 
growing scale because of the introduction 
of new indications and the aging of the 
population.8-12 However, prospective stud-
ies examining the risk of the implantation 
procedure or the complications after ini-
tial implantation or replacement of cardi-
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ac rhythm management devices (CRMDs) are rare.13
The primary aim of the present study was to es-
timate prospectively the complication rates, over a 
2-year follow-up period, associated with the initial 
implantation or replacement of CRMDs that were 
implanted during a 1-year period in one tertiary uni-
versity hospital in Greece. A secondary goal was to 
examine the additional hospital stay due to these 
complications and their economic implications.
Methods
Study design and sampling
This is a single-center registry that formed part of a 
cost-of-illness study. We recorded data from a con-
secutive series of patients who underwent CRMD im-
plantation or replacement during a period of 1 year. 
The implantations of ICDs were conducted after ap-
proval from the Central Council of Health, as re-
quired by Greek legislation. Oral informed consent 
was obtained from the patients at the initial visit, pri-
or to proceeding with the study. The study was car-
ried out in accordance with the Declaration of Hel-
sinki of 1975, as revised in 2000.
Data collection
Three case report forms (CRFs)—one for the base-
line data (CRF A), another for the follow-up data 
(CRF B), and the last one at the end of the study 
(CRF C)—for each enrolled patient were completed 
prospectively by the investigator of the study.
CRF A (baseline data) encompasses sociode-
mographic characteristics, measurements of anthro-
pometric and clinical characteristics, type of device 
(manufacturer, serial number), number and type of 
electrodes (manufacturer, serial number), and finally 
the complications during the implantation procedure. 
All these data were recorded by the principal inves-
tigator of the study from face-to-face interviews with 
the patients, from their medical folders and their at-
tending physician.
CRF B (follow-up data) records all the complica-
tions that were noted during the follow-up period.
CRF C represents the final report at the end of 
the study for each patient. In case of death, the date 
and cause of death were recorded.
Study population
In the study period a total of 464 patients underwent 
initial implantation or replacement of a CRMD. Of 
these, 29 were lost during the two-year follow-up pe-
riod and 37 patients died for reasons unrelated to 
their devices or other cardiac cause. Finally, data 
from 398 patients were analyzed.
Definition of complication
We defined as complication any adverse event related 
to CRMD therapy requiring reoperation or addition-
al diagnostic examination, with the subsequent need 
for prolongation of hospital stay.
Results
Complications at initial implantation of PM
From the 240 initial PM implantations, 16 patients 
were lost to follow up and 23 died from non-cardiac 
causes (Table 1).
Among the 201 patients who remained, seven 
complications occurred in 6 patients (2.99%). More 
specifically, 5 patients suffered 6 lead dislodgements 
(1 patient twice). In 3 cases the passive lead was re-
placed with an active one; in the other 2 cases the 
lead was repositioned, but in 1 of them it was re-
placed by a new active lead, as it was dislodged again. 
One of the patients who had lead dislodgement died 
Table 1. Complication rates in patients undergoing PM and ICD during the procedure of implantation and in two years’ follow up.
Device implantations PM (n=370) ICD (n=94)
 Initial Replacement Initial Replacement
Number of patients 240 130 80 14
Died in 2-year follow up (non-cardiac causes) 23 7 5 2
Lost to follow up 16 6 6 1
Completed follow up (2 years) 201 117 69 11
Patients with complication 6 1 0 0
Number of complications 7 1 0 0
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from non-cardiac causes before he completed the fol-
low up.
A pocket erosion was the most important com-
plication that occurred in 1 patient, where the blood 
cultures revealed S. epidermidis. The entire system 
was extracted and the patient received the appropri-
ate antibiotics for 4 weeks. A well-trained multidisci-
plinary team was needed in order to ensure an effec-
tive pacing system extraction.14
Complication at replacement of PM
From the 130 PM replacements, 6 patients were lost 
in the follow-up period and 7 patients died from non-
cardiac causes (Table 1).
Of the remaining 117 patients, 1 female patient 
(0.85%) had an erosion in the pocket, which was re-
vised successfully, but died from a non-cardiac cause 
before the end of the follow up.
Complication at initial implantation of ICD
From the 80 initial ICD implantations, 6 patients 
were lost to follow up and 5 died from non-cardiac 
causes. There were no complications (0.0%) among 
the remaining 69 patients who completed the 2-year 
follow up (Table 1).
Complication at replacement of ICD
From the 14 ICD replacements, 1 patient was lost 
to follow up and 2 patients died from non-cardiac 
causes. None of the remaining 11 patients who com-
pleted the 2-year follow-up period had any kind of 
complication (Table 1).
Time of occurrence of complications and additional 
hospital stay
In total (from initial implantations and replacements 
of PM and ICD), there were 7 patients (5 males and 
2 females) who suffered eight complications. Regard-
ing lead dislodgements, 3 of them occurred acutely 
(within 24 hours from the procedure) and reopera-
tion was performed less than 48 hours after the pro-
cedure. The other 3 occurred 4, 5, and 19 days after 
the initial procedure. Reoperation was performed 
within 24 hours.
The pocket infection, which was revealed 400 
days after the procedure in an 80-year-old male, was 
the seventh complication, while the last complication 
was a pocket erosion, revealed 100 days after a PM 
replacement procedure in an 81-year-old female.
All the complications resulted in 51 additional 
hospital treatment days. The average prolongation 
of the hospital stay was 7 days, ranging from 1 to 35 
days.
Financial implications of complications
In an attempt to assess the financial implications 
of the complications, they were analyzed over a 
24-month period after the procedure, in order to esti-
mate the additional cost of complicated care.
We estimated the additional direct cost (hospi-
talization cost, medication cost, laboratory and im-
aging diagnostic examinations) using the bottom-
up approach. Based on 2012 charges, we estimated 
the total additional cost due to complications to be 
€17,411.
Discussion
In our study, the percentage of complications over 
a follow-up period of 2 years in patients who under-
went PM implantation was 2.99% for initial implants 
and 0.85% for replacements. In contrast, no com-
plications were recorded in patients who underwent 
ICD initial implantation or replacement.
The most common complication was lead dis-
lodgement, while the most serious complication was 
pocket infection and endocarditis, which occurred in 
1 patient.
Compared to other studies the complication rates 
from our study are relatively low.15-21
Acute complications (atrial and/or ventricular 
lead displacement requiring repositioning, infection, 
pneumothorax, hemothorax, cardiac tamponade, 
acute myocardial infarction, and death) after initial 
PM implantations are not rare, ranging from 4-7%.19
A registry-based prospective multicenter study 
(FOLLOWPACE)15 reported serious implantation-
related in-hospital complication rates for patients un-
dergoing initial PM implantation. Based on the first 
1198 non-selected patients from this registry, 111 
patients (10.1%) exhibited one or more complica-
tions. More recent data from the same study,16 based 
on 1517 patients who underwent initial PM implan-
tation, demonstrated a complication rate of 12.4% 
(during the procedure and within 2 months). Thereaf-
ter, over a period of 5.8 years, 140 (9.2%) patients ex-
perienced complications, mostly lead related (n=84).
36 • HJC (Hellenic Journal of Cardiology)
J. Fanourgiakis et al
The activity and experience of operators are criti-
cal for the number and the type of complications. Ac-
cording to Parsonnet et al22 and Tobin et al,19 the re-
lation between operator experience and complication 
rates is linear. Moreover, Tobin et al19 reported that 
operators with more than 10 years’ experience and 
more than 40 cases per year have the lowest percent-
age of complications.
In accordance with this, one study21 reported 
that, in 234 PM implantations performed by cardiolo-
gists, the complication rate was 7.7%, whereas in 242 
PM implantations performed by trainees, the com-
plication rate was 17.4%. In total, 78 complications 
occurred in 60 patients (12.6%) and 8 patients had 
more than 1 complication. The most common com-
plication in this study, during the PM implantation 
procedure and the follow-up period up to 3 months, 
was lead dislodgement in 21 (3.7%) patients (6 mac-
ro- and 15 microdislodgements). The overall compli-
cation rate did not differ between single- and dual-
chamber PM devices.
It is not clear whether the complication rate was 
higher with dual- or with single-lead implantations. 
Some authors20 have reported a higher rate of com-
plications with dual-chamber than with single-cham-
ber pacemakers. Others24 have reported no increase 
in complication with dual-chamber pacemakers com-
pared to single-chamber systems. A study from Pap-
worth20 reported higher late complication rates after 
elective unit replacement of dual-chamber systems.
At the same time, patients who underwent ICD 
implantation in our centre had no complications dur-
ing 2 years’ follow up, following either initial implan-
tation or device replacement. It notable that no such 
results have been reported, either in any other similar 
study worldwide,13,21,24-26 or in one systematic review 
of a randomized clinical trial.27
One single-center retrospective study21 report-
ed complication rates of 9.9% in patients undergo-
ing ICD and CRT device implantations over a short-
term follow up (<3 months). Another study,28 which 
aimed to assess cardiac device implantations in the 
USA from 1997 through 2004 and to estimate periop-
erative outcomes until discharge, concluded that one 
or more complications occurred in 2-4% of new im-
plantations.
The most important complication and the night-
mare for operators and patients is infection, which can 
be associated with substantial morbidity and mortality.
The PEOPLE study24 was a multicenter study 
from 44 medical centers, which evaluated the inci-
dence and the risk factors of infectious complications 
over a follow-up period of 12 months after PM and 
ICD implantations in 6319 consecutive patients, 5866 
with PM and 453 with ICD devices. Infections devel-
oped in 42 patients who underwent PM and ICD im-
plantation, representing an incidence of 0.68 per 100 
patients.
According to one survey,29 which analyzed data 
from 48 centers of the European Heart Rhythm As-
sociation (EHRA) Research Network, the incidence 
of cardiovascular implantable electronic device infec-
tions showed a slight decrease from 2010 to 2011 in 
most centers and was substantially under 2% in the 
majority of centers interviewed. Fortunately, in our 
centre we had only 1 patient with pocket infection, 
which occurred long after the implantation proce-
dure. However, it is clear that pocket infection is the 
complication with by far the longest additional hos-
pital stay (35 days) and the greatest additional cost 
(€11,200).
The results from our study are very encouraging 
because of the low rates of complications. These low 
rates were mainly due to the high level of experience 
of the medical team. The team that has the responsi-
bility for CRMD implantations receives continuous 
education on the technical, medical, and procedural 
levels and consists of cardiologists and electrophysiol-
ogists with a long experience in device therapy: more 
than 15 years of experience, and more than 5000 pro-
cedures involving implantation of such devices. The 
experienced operating room staff is also important. 
All of the above characteristics contribute to a careful 
and personalized clinical appraisal for each patient.
Study limitations
This study reflects complication rates from one cen-
ter and the study population was relatively small. To 
assess more reliable individual determinants of com-
plications, the study population should be larger, 
with a longer follow-up period. Ideally, all patients 
would be followed until death or need for replace-
ment of the device. In addition, this study was not de-
signed to evaluate the relationship of individual pa-
tient risk factors and subsequent complications. We 
present percentages of complications and compare 
those rates with the rates from other studies, but we 
cannot make accurate comparisons with those studies 
because of the differences in the follow-up period, in 
the types of devices, and the clinical and demographic 
profile of the enrolled patients.
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Conclusion
This prospective survey demonstrates relatively low 
complication rates of in patients undergoing CRMD 
implantation, initial or replacement, in our center 
compared with other studies. The additional hospital-
ization days and the cost attributed to these complica-
tions depend on the nature of the complication.
The strength of the present report is that data 
were gathered in an organized, prospective fashion, 
within the confines of a randomized clinical trial. 
Quality assessment of therapeutic procedures of the 
CRMDs is essential in order to ensure a cost-effec-
tive health care system, especially today, in an era of 
sharp economic decline. Based on these complica-
tion rates, there is currently no evidence to support a 
change in practice.
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